Edesa Biotech, Inc.
EDSA
Rank in Stocks
#26713
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering,... Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Share Price
$1.96
Last synced: 2026-11-17
Market Cap
$17.65M
Change (1 day)
3.70%
Change (1 year)
15.29%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Edesa Biotech, Inc. (EDSA)
Category
Healthcare
EPS for Edesa Biotech, Inc. (EDSA)
EPS as of June 2026 TTM: $-1.69
According to Edesa Biotech, Inc.'s latest financial reports, its current EPS (TTM) is $-1.69. At the end of 2025 the company had an EPS of $-1.27, an increase over its 2024 EPS of $-1.93.
EPS history for Edesa Biotech, Inc. from 2009 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-1.69 | 33.07% |
| 2025 | $-1.27 | -34.20% |
| 2024 | $-1.93 | -34.13% |
| 2023 | $-2.93 | -64.99% |
| 2022 | $-8.37 | 8.28% |
| 2021 | $-7.73 | 49.23% |
| 2020 | $-5.18 | 8.14% |
| 2019 | $-4.79 | 44.28% |
| 2018 | $-3.32 | -90.97% |
| 2017 | $-36.78 | 53.76% |
| 2016 | $-23.92 | 59.36% |
| 2015 | $-15.01 | -67.89% |
| 2014 | $-46.75 | -61.41% |
| 2013 | $-121.14 | 142.96% |
| 2012 | $-49.86 | -36.19% |
| 2011 | $-78.14 | 392.07% |
| 2010 | $-15.88 | 107.04% |
| 2009 | $-7.67 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -1,026.63% |
US
|
|
| $-7.07 | 318.34% |
US
|
|
| $-5.29 | 213.02% |
AU
|
|
| $12.73 | -853.38% |
BE
|
|
| $21.56 | -1,375.74% |
NL
|
Questions about Edesa Biotech, Inc.'s earnings per share (EPS)
What is Edesa Biotech, Inc.'s earnings per share (EPS)?
Edesa Biotech, Inc.'s earnings per share (EPS) over the last twelve months is $-1.69, as of Jun 2026.
What was Edesa Biotech, Inc.'s earnings per share (EPS) in 2025?
In 2025, Edesa Biotech, Inc.'s earnings per share (EPS) was $-1.27, compared with $-1.93 in 2024.
How has Edesa Biotech, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Edesa Biotech, Inc.'s earnings per share (EPS) was highest in 2025 ($-1.27) and lowest in 2022 ($-8.37).
How does Edesa Biotech, Inc.'s earnings per share (EPS) compare with similar companies?
Edesa Biotech, Inc.'s earnings per share (EPS) ($-1.69) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.